Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)

被引：0

作者：

Bennouna, J. ^{[1
]}

Hiret, S. ^{[2
]}

Borg, C. ^{[3
]}

Bertaut, A. ^{[4
]}

Bouche, O. ^{[5
]}

Deplanque, G. ^{[6
]}

Francois, E. ^{[7
]}

Conroy, T. ^{[8
]}

Ghiringhelli, F. ^{[9
]}

des Guetz, G. ^{[10
]}

Seitz, J-F. ^{[11
]}

Artru, P. ^{[12
]}

Stanbury, T. ^{[13
]}

Charpentier, S. ^{[14
]}

Denis, M. ^{[14
]}

Adenis, A. ^{[15
]}

机构：

[1] CHU Nantes, IMAD Digest Oncol, Nantes, France

[2] Inst Cancerol Ouest, Med Oncol, St Herblain, France

[3] CHU Besancon, Med Oncol, Besancon, France

[4] Georges Francois Leclerc Canc Ctr, Biostat, Dijon, France

[5] CHU Reims, Gastroenterol, Reims, France

[6] Hop Riviera Chablais, Med Oncol, Vevey, Switzerland

[7] Ctr Antoine Lacassagne, Med Oncol, Nice, France

[8] Inst Cancerol Lorraine, Med Oncol, Vandoeuvre Les Nancy, France

[9] Georges Francois Leclerc Canc Ctr, Med Oncol, Dijon, France

[10] CHU St Denis, Med Oncol, Limoges, France

[11] APHM, Gastroenterol, Marseille, France

[12] Hop Prive Jean Mermoz, Gastroenterol, Lyon, France

[13] UNICANCER, Invest Ctr, Paris, France

[14] CHU Nantes, Mol Biol, Nantes, France

[15] Ctr Oscar Lambret, Med Oncol, Lille, France

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

477O

引用

页数：2

共 50 条

[21] Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data
Kubackova, Katerina
Bortlicek, Zbynek
Pikus, Tomas
Linke, Zdenek
Pokorna, Petra
Vyzula, Rostislav
Prausova, Jana
FUTURE ONCOLOGY, 2015, 11 (02) : 225 - 232
[22] Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients
Stintzing, S.
Jung, A.
Rossius, L.
Modest, D. P.
von Weikersthal, L. Fischer
Decker, T.
Moehler, M.
Scheithauer, W.
Kirchner, T.
Heinemann, V.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S8 - S9
[23] Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial
Shiozawa, Manabu
Sunakawa, Yu
Watanabe, Takanori
Ota, Hirofumi
Yasui, Hisateru
Yabuno, Taichi
Tei, Mitsuyoshi
Kochi, Mitsugu
Manaka, Dai
Ohori, Hisatsugu
Yamaguchi, Tatsuro
Sagawa, Tamotsu
Kotaka, Masahito
Kubota, Yutaro
Sekikawa, Takashi
Nakamura, Masato
Takeuchi, Masahiro
Ichikawa, Wataru
Fujii, Masashi
Tsuji, Akihito
NATURE COMMUNICATIONS, 2024, 15 (01)
[24] Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC)
Schwartzberg, Lee Steven
Rivera, Fernando
Karthaus, Meinolf
Fasola, Gianpiero
Canon, Jean-Luc
Yu, Hua
Oliner, Kelly S.
Go, William Y.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[25] An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (BEV) in metastatic colorectal cancer (MCRC)
Hecht, J.
Chiciac, T.
Mitchell, E.
Stella, P.
Cohn, A.
McCollum, D.
Saleh, M.
Marshall, A.
Shahin, S.
Deeter, R.
ANNALS OF ONCOLOGY, 2007, 18 : VII21 - VII22
[26] Panitumumab after progression on cetuximab in patients with KRAS wild-TYPE (WT) metastatic colorectal cancer (MCRC): A single institution experience
Marino, Antonella
Caliolo, Chiara
Sponziello, Francesco
Nacci, Angelo
Quaranta, Annamaria
Mazzoni, Enrica
Federico, Federica
Rizzo, Pietro
Calvani, Nicola
Orlando, Laura
Schiavone, Paola
Fedele, Palma
Amico, Maria D'
Chetri, Maria Concetta
Cinefra, Margherita
Ferrara, Pasqualinda
Cinieri, Saverio
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[27] FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO
Marmorino, F.
Cremolini, C.
Bergamo, F.
Pella, N.
Antoniotti, C.
Rossini, D.
Dell'Aquila, E.
Masi, G.
Salvatore, L.
Loupakis, F.
Marcucci, L.
Gemma, D.
Cardellino, G.
Borelli, B.
Ricci, V.
Delfanti, S.
Mori, E.
Tonini, G.
Lonardi, S.
Fontanini, G.
Boni, L.
Falcone, A.
ANNALS OF ONCOLOGY, 2018, 29
[28] Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings
Kubicka, S.
Greil, R.
Andre, T.
Bennouna, J.
Sastre, J.
Van Cutsem, E.
von Moos, R.
Oesterlund, P.
Reyes-Rivera, I.
Mueller, T.
Makrutzki, M.
Arnold, D.
ANNALS OF ONCOLOGY, 2013, 24 (09) : 2342 - 2349
[29] Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab plus chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer
Aparicio, T.
Bouche, O.
Francois, E.
Retornaz, F.
Barbier, E.
Taieb, J.
Kirscher, S.
Etienne, P-L.
Faroux, R.
Akouz, F. Khemissa
El Hajbi, F.
Locher, C.
Rinaldi, Y.
Lecomte, T.
Lavau-Denes, S.
Baconnier, M.
Oden-Gangloff, A.
Genet, D.
Bedenne, L.
Paillaud, E.
EUROPEAN JOURNAL OF CANCER, 2018, 97 : 16 - 24
[30] SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second -line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).
Hecht, J. Randolph
Cohn, Allen Lee
Dakhil, Shaker R.
Saleh, Mansoor N.
Piperdi, Bilal
Cline-Burkhardt, Vivian Jean M.
Tian, Ying
Go, William Y.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)

← 1 2 3 4 5 →